Erin Anderson
Family · Overland Park, KSNPI 1417503491
Payments from drug & device makers
Across 162 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$480
- Johnson & Johnson$293
- Novo Nordisk$234
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$214
- Novartis$214
- Boehringer Ingelheim$149
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,947100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 22 | $480 |
| Johnson & Johnson | 18 | $293 |
| Novo Nordisk | 12 | $234 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $214 |
| Novartis | 13 | $214 |
| Boehringer Ingelheim | 11 | $149 |
| Merck | 9 | $143 |
| Sanofi-aventis U.S. LLC | 8 | $141 |
| AstraZeneca | 9 | $138 |
| Bayer | 8 | $136 |
| E.r. Squibb & Sons, L.L.C. | 8 | $125 |
| Pfizer | 8 | $123 |
| Actelion Pharmaceuticals US, Inc. | 6 | $103 |
| Daiichi Sankyo Inc. | 4 | $84 |
| Revance Therapeutics, Inc. | 2 | $53 |
| Lexicon Pharmaceuticals, Inc. | 3 | $47 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $42 |
| Medtronic | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 2 | $33 |
| Cvrx, Inc. | 2 | $28 |
| Dexcom, Inc. | 1 | $28 |
| Amarin Pharma, Inc. | 1 | $19 |
| Atricure, Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
| Boston Scientific | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $13 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,947 in reported general payments places this provider in the 90th percentile of 1,579 family providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $24,020 |
| Flecainide Acetate | 11 | $539 |
| Metoprolol Succinate | 45 | $452 |
| Atorvastatin Calcium | 50 | $350 |
| Losartan Potassium | 33 | $196 |
| Lisinopril | 16 | $161 |
| Amlodipine Besylate | 39 | $129 |
| Hydrochlorothiazide | 12 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $123 | $24,02030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,579 family providers in Kansas.
Other family in Overland Park
- Jennifer ChesterOverland Park$327K
- Erin FeitzOverland Park$36K
- Tracy GraebenerOverland Park$29K
- Kathryn TimmOverland Park$14K
- Lauren BarberOverland Park$12K
- Tracy HillOverland Park$8K
- Matthew NitschOverland Park$7K
- Gretchen PolandOverland Park$7K
- Anaya KoleOverland Park$7K
- Geneva BealOverland Park$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.